Role of mTOR inhibitors in kidney disease

Pharmacology, Toxicology and Pharmaceutical Science

• Mammalian Target of Rapamycin 100%
• Mammalian Target of Rapamycin Inhibitor 100%
• Sirolimus 100%
• Anticarcinogen 66%
• Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone) 66%
• Kidney Disease 66%
• Diabetic Nephropathy 33%
• Adenosine Triphosphate 33%
• Immunosuppressive Agent 33%
• Everolimus 33%
• Clinical Trial 33%
• Solid Malignant Neoplasm 33%
• Antiproliferative Activity 33%
• Molecular Target 33%
• Kidney Cancer 33%
• Soil Microflora 33%
• Temsirolimus 33%
• Mammalian Target of Rapamycin Complex 1 33%
• Competitive Inhibitor 33%
• Rapamycin 33%